ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.